Becoming a global leader in biosimilars development
Leadership Team
Our Promoters
P.V. Ram Prasad Reddy
Non-Executive Director
K. Nityananda Reddy
Vice Chairman & Managing Director
Latest News
Press Release
07 April 26
Aurobindo arm CuraTeQ reports positive Phase 3 results for allergy drug BP11
Aurobindo Pharma unit CuraTeQ reports positive Phase 3 data for Xolair biosimilar BP11 in chronic spontaneous urticaria, plans EMA and FDA filings by end of Q2 2026
Read More
Press Release
12 February 26
Aurobindo Pharma Targets 2029 as Turning Point for Its Biosimilars Business
Aurobindo Pharma expects its biosimilars division to become a major growth driver, targeting 2029 as a key turning point with expansion across Europe, the US, and emerging global markets.
Read More
Press Release
19 September 25
CuraTeQ Biologics announces positive Phase 3 study results for Denosumab biosimilar
Read More
Press Release
04 July 25
CuraTeQ Biologics receives EC marketing authorization for Dazublys – Trastuzumab biosimilar
Read More
Press Release
26 April 25
CuraTeQ Biologics receives CHMP positive opinion for Dazublys – Trastuzumab biosimilar
Read More
Press Release
10 April 25
CuraTeQ Biologics successfully completes Phase I study for Denosumab biosimilar
Read More
Press Release
31 January 25
CuraTeQ Biologics receives CHMP positive opinion for Pegfilgrastim biosimilar
Read More
Press Release
21 December 24
CuraTeQ Biologics receives UK MHRA approval for Bevqolva™ (Bevacizumab biosimilar)
Read More
Press Release
13 December 24